SAGE Journals Online
Advertisement
Sign In to gain access to subscriptions and/or personal tools.

 

Advanced Search

Journal Navigation

Journal Home

Subscriptions

Archive

Contact Us

Table of Contents

Advertisement

Sign In to gain access to subscriptions and/or personal tools.
Perspectives in Vascular Surgery and Endovascular Therapy
This Article
Right arrow Full Text (PDF)
Right arrow References
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Email this article to a friend
Right arrow Similar articles in this journal
Right arrow Alert me to new issues of the journal
Right arrow Add to Saved Citations
Right arrow Download to citation manager
Right arrowRequest Permissions
Right arrow Request Reprints
Right arrow Add to My Marked Citations
Citing Articles
Right arrow Citing Articles via Google Scholar
Right arrow Citing Articles via Scopus
Google Scholar
Right arrow Articles by Matsuura, J. H.
Right arrow Articles by Rosenthal, D.
Right arrow Search for Related Content
PubMed
Right arrow Articles by Matsuura, J. H.
Right arrow Articles by Rosenthal, D.
Social Bookmarking
Add to CiteULike   Add to Complore   Add to Connotea   Add to Del.icio.us   Add to Digg   Add to Reddit   Add to Technorati   Add to Twitter  
What's this?

The Role of Cryopreserved Femoral Vein Graft in Hemodialysis Access Surgery

John H. Matsuura, M.D., F.A.C.S.

Medical College of Georgia; Vascular Surgery, Atlanta Medical Center, Atlanta, GA.

David Rosenthal, M.D., F.A.C.S.

Medical College of Georgia; Vascular Surgery, Atlanta Medical Center, Atlanta, GA.

Cryopreserved allografts have demonstrated resistance to infection similar to that of autogenous tissue when used for the treatment of prosthetic arterial bypass graft infections. As the number of hemodialysis access procedures increases, prosthetic hemodialysis graft infection has become a significant problem. We have used the cryopreserved femoral vein as an alternative conduit in the treatment of prosthetic arteriovenous (AV) hemodialysis graft infections. Forty-eight cryopreserved femoral vein AV graft procedures were performed. The 1-year primary graft patency rate was 49%, while the secondary graft patency rate was 75%. No subsequent cryopreserved allograft infections occurred. The cryopreserved femoral vein graft is a safe, durable, and infection resistant conduit for the treatment of prosthetic AV hemodialysis graft infections.

Key Words: Cryopreserved femoral vein • infected prosthetic bypass graft

Perspectives in Vascular Surgery and Endovascular Therapy, Vol. 13, No. 1, 71-80 (2000)
DOI: 10.1177/153100350001300111
Add to CiteULike CiteULike   Add to Complore Complore   Add to Connotea Connotea   Add to Del.icio.us Del.icio.us   Add to Digg Digg   Add to Reddit Reddit   Add to Technorati Technorati   Add to Twitter Twitter    What's this?




Advertisement